Retrospective database study from Japan of PsA pts: At 12/24 mos ffg tx initiation, 37.5%/49% of pts discontinued index bDMARD while 22.2%/31.2% switched tx. Dc rates lowest for risankizumab 🤔Reasons for switching/discontinuation not mentioned. #ACR23 ABST2246 @RheumNow https://t.co/6dhKZmp1wE